Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Google Secures Pentagon AI Deal for Classified Projects 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
MALVERN, Pa., April 25, 2017 -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biopolymer-based drugs for the treatment of orphan diseases with an initial focus on cardiopulmonary disorders, today announced that Vice President of Research & Scientific Affairs Jim Ballance, Ph.D., will present preclinical and clinical data on the company’s proprietary elastin-like polypeptide (ELP) biopolymer technology platform in an oral session at the TIDES: Oligonucleotide & Peptide Therapeutics conference to be held April 30 - May 3 at the Manchester Grand Hyatt in San Diego, CA.
Details on the presentation are as follows:
Title: Elastin-Like Polypeptide Biopolymers Enhance the Pharmacology of Therapeutic Peptides
Track: Peptide Discovery, Preclinical and Clinical
Session: Peptides in the Clinic: Lessons Learned
Date / time: Tuesday, May 2, 3:05 - 3:30 p.m. PDT
Location: Cortez Hill
For additional information on the conference, please visit: https://lifesciences.knect365.com/tides/.
About PhaseBio
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing new and improved biotherapeutics for the treatment of orphan diseases, with a focus on cardiopulmonary disorders. The company’s proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which can lead to less-frequent dosing and better patient compliance. PhaseBio's lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension (PAH); the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy; and the treatment of cystic fibrosis. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit www.phasebio.com.
Media Contact: Laura Bagby, 6 Degrees (312) 448-8098 [email protected]
